Cargando…
Influence of TNFα–308 and T676G TNF-RII polymorphism on response to etanercept and posibility to discontinue tretment
Autores principales: | Vojinovic, J, Susic, G, Lazarevic, D, Basic, J, Nikolic, I, Damjanov, N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194643/ http://dx.doi.org/10.1186/1546-0096-9-S1-P277 |
Ejemplares similares
-
DNase I levels in JIA – influence of anti-TNF (etanercept) therapy
por: Vojinovic, J, et al.
Publicado: (2008) -
DNase I levels and disease outcome in JIA patients treated with etanercept
por: Lazarević, D, et al.
Publicado: (2011) -
Inflence of clinical and genetic characteristics on ability to achive and maintain remission in JIA patients on etanercept treatment
por: Lazarevic, Dragana S, et al.
Publicado: (2014) -
Influence of Promoter Polymorphisms of the TNF-α (-308G/A) and IL-6 (-174G/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis
por: Jančić, Ivan, et al.
Publicado: (2015) -
Bone mineral density improvement after one year of treatment with etanercept in patients with juvenile idiopathic arthritis
por: Susic, G, et al.
Publicado: (2008)